NCT07400679
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity
Completed
PHASE1Ages 18+InterventionalBasic sciencePfizer
~48 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:PF-08653944
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944
Measured over Up to 85 days
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesConnecticut1
Study leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants 18 years of age or older at Screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
BMI of 27-45 kg/m2 ; and a total body weight \>50 kg (110 lb).
For Japanese participants only: BMI of 20-45 kg/m2 and a total body weight \>50 kg (110 lb) and must have 4 biological Japanese grandparents who were born in Japan.
Exclusion
Pregnant or breastfeeding women, or those planning pregnancy during the study.
Clinically significant medical conditions including hematologic, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis, gallbladder disease, clinically relevant gastric emptying disorders), cardiovascular, hepatic, psychiatric, neurologic, or severe allergic diseases.
Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC.
Active or recent suicidal ideation in the past year, suicidal behavior within the past 5 years, or any psychiatric condition that increases risk in the investigator's judgment.
Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect GI motility.
Acute gastrointestinal symptoms at screening or Day -1.
Known hypersensitivity to PF-08653944, GLP-1 receptor agonists, or any excipients.
Prior participation in any study involving PF-08653944 (formerly MET097) with at least one dose received.
What this trial measures
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944Up to 85 days
To assess the relative bioavailability of SC to the thigh or upper arm compared to the abdomen
- PK: Maximum Observed Concentration (Cmax) of PF-08653944Up to 85 days
To assess the relative bioavailability of SC to the thigh or upper arm compared to the abdomen